Ken Griffin Contrafect Corp Call Options Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2022

Feb 14, 2023
SELL
$0.09 - $0.19 $1,206 - $2,546
-13,400 Reduced 36.51%
23,300 $2,000
Q3 2022

Nov 14, 2022
SELL
$0.18 - $3.51 $6,966 - $135,837
-38,700 Reduced 51.33%
36,700 $6,000

Others Institutions Holding CFRX

# of Institutions
2
Shares Held
49.2K
Call Options Held
0
Put Options Held
0
View Full List

About CONTRAFECT Corp

CFRX Quotes by TradingView
  • Ticker CFRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,332,700
  • Market Cap $1.18M
  • Description
  • ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...
More about CFRX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email